Informa Australia is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
17 Nov 2010, by Informa Insights
Melbourne, 17th November 2010 – Despite growing at a compound annual growth rate of more than 24% over the last five years, the testosterone replacement therapy market is severely underdeveloped. This suggests there are great opportunities for pharmaceutical companies in this field, claims independent market analyst, Datamonitor*.
The testosterone replacement therapy market, valued at $838m across the seven major markets** is far from saturated, with only an estimated 5% of people affected by the disorder receiving treatment.
Over 57 million men across the seven major markets suffer from testosterone deficiency syndrome, also known as male hypogonadism. Studies suggest that up to 50% of men could have very low levels of testosterone leading to a variety of symptoms including decreased muscle mass, decreased libido and erectile dysfunction. Treatment consists of restoring the hormone levels in the body through testosterone replacement therapy.
Maya Marescotti, healthcare analyst at Datamonitor, comments: “Given the low diagnosis and treatment rates, there is an opportunity for companies to invest resources and develop the market. Common strategies to raise awareness include didactic symposia for physicians and educational campaigns in the media for the public.”
The US is by far the largest market, accounting for over 95% of sales in 2009 and was also the fastest growing.
Going forward, Datamonitor expects the market, which is driven primarily by topical formulation, to display growth, reaching $1.4 billion in 2019. However, growth will be slower to the generic incursion for key products such as Androgel (testosterone gel, Abbott/Solvay) and Androderm (testosterone patch; Watson) in the US. While all drugs have similar efficacy and side-effect profiles, drugs will have to mainly differentiate on price and formulations.
Assuming FDA approval, Eli Lilly is expected to launch Axiron (testosterone)—the first underarm metered dose spray, developed by Australian drug delivery company Acrux—in 2011. Eli Lilly will be able to drive Axiron’s sales, which will reach over $370m in 2019, by leveraging its sales and marketing resources as well as its experience in the men’s health sector with blockbuster drug Cialis (tadalafil).
Informa Connect Australia is the nation's leading event organiser. Our events comprise of large scale exhibitions, industry conferences and highly specialised corporate training.
